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Abstract 
   The goal of the present study is to investigate the role of metformin (MF) 
as a target of miRNAs in breast cancer resistant protein (BCRP) inhibition in 
an attempt to develop treatment strategies that may improve the response of 
breast cancer (BC) patients to chemotherapy (CT). In order to fulfill this 
target, non-diabetic female subjects were categorized into three groups: 
control group (group 1) (n=5), CT group of BC patients (group 2) (n=25) and 
CT plus MF group of BC patients (group 3) (n=25). All patients were 
subjected to full history taking, laboratory studies including mammogram, 
chest X-ray, pelvic-abdominal ultrasound and isotopic bone scan, in addition 
to ER and PR states. CT group was treated with neoadjuvent CT in the form 
of 5-FU (500 mg/m2), Adriamycin (50 mg/m2) and cyclophosphamide (500 
mg/m2). Flow cytometry (FC) of BCRP and MiRNA was carried out on 
blood samples at every cycle of treatment for all partners. 
  The results showed the presence of miRNA was higher than the presence of 
BCRP in the normal healthy control group. In most cases of CT and CT plus 
MF groups (group 2, 3) it was well noticed that the amount of BCRP in the 
blood samples exceeded that of miRNA illustrated the dysregulation of 
miRNA in BC patients and also to prove the basic role of BCRP as a 
multidrug resistance (MDR) for chemotherapeutic agents in patients with 
BC. 
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It is concluded that the role of MF was well proved in targeting of miRNA to 
reinforce BC medication, so oncologists can be advised to use MF equivalent 
to CT in the recommended doses. 
 
Keywords:  Breast cancer, Breast cancer resistant protein, Chemotherapy, 
Flow cytometry, Metformin, Multidrug resistance, microRNAs. 
 
Introduction 
Breast cancer is the most commonly diagnosed cancer and worldwide 
it is considered the leading cause of cancer death in females, accounting for 
23% (1.38 million) of the total new cancer cases and 14% (458,400) of the 
total cancer deaths  (Anderson et al., 2008). 
Approximately half of the BC cases and 60% of the deaths are 
estimated to take place in developing countries, In Egypt, the median age at 
diagnosis for BC is ten years younger than in the United States and Europe 
(Omar et al., 2003).Cancer in young is generally more aggressive and results 
in lower survival rates, making early detection even more crucial and 
emphasizing the importance to raise BC awareness among young females 
(Sambanje et al., 2012). 
Chemotherapy (CT) plays a key role in the treatment of BC; however, 
the widespread resistance to CT often results in the treatment failure. Drug 
resistance to chemotherapeutic agents accounts for treatment failure in more 
than 90% of patients with metastatic cancer. 
Metformin (MF), the most common first-line drug in the treatment of 
type-2 diabetes, has been shown in previous studies to reduce BC risk, 
improve survival, and increase the effectiveness of CT. 
The discovery of miRNAs has opened new avenues for BC metastasis 
research. Several lines of evidence now link miRNA dysregulation to 
carcinogenesis, progression, chemoresistance and recurrence in several 
cancers. Many recent studies on BC have clearly demonstrated that miRNAs 
can play an important role in the multistep process of metastasis, functioning 
as both activators and suppressors of metastasis by critically regulating various 
stages of migration and invasion. In BC, the expression levels of several 
miRNAs are significantly different between normal and cancerous tissues and 
between BCs of different molecular subtypes with a different prognosis. This 
study aimed to investigate the role of MF as a target of miRNAs in BCRP 
inhibition in an attempt to develop treatment strategies that may improve the 
response of breast cancer patients to chemotherapy. 
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Methods 
Subjects 
This study included 55 non-diabetic females aged from 37-70 years old, 
after written informed consent. Fifty patients were selected with histological 
proved BC patients admitted to Cancer Research and Management 
Department, Medical Research Institute, Alexandria University. Five 
volunteers of apparently normal breast and with comparable characteristics 
served as control group. Patients were subjected to: 
Full history taking thorough clinical examination, laboratory studies 
including complete blood count, kidney and liver function tests, tumor 
markers (CEA and CA15.3), radiological examination including mammogram, 
chest X-ray, pelvic-abdominal ultrasound, isotopic bone scan and estrogen and 
progesterone receptors states. 
 
Study design and treatment 
Non-diabetic female subjects were categorized in three groups: control 
group (group1) (n=5), CT group of BC patients (group 2) (n=5) and CT plus 
MF group of BC patients (group 3) (n=25). Before every cycle of treatment, 
blood samples from all participants were used to determine the following 
parameters: 
 
(1) Preparation of blood cells 
Blood was collected from patients in the different groups and blood 
films were left to air dry. The slides were flood with Leishman's stain 
solution, wait for 8 minutes and then flood off with distilled water in 2 – 3 
seconds.  
 
(2) Flow cytometry of BCRP and miRNAs. 
In summary, three tubes were taken, the first was for the negative 
control; the second was for anti-DDX6/RCK for miRNA and the third was 
for anti-BCRP. 
Red blood corpuscles and platelets were lysed using lysing agent to see 
the antibodies (Abs) on the white blood corpuscles. 50µ of blood were taken 
and left for 20 minutes. The pellet was formed by vortex centrifuge for 3000 
RPM. Wash by PBS after incubation for 30 minutes. The acquisition step 
was carried out to stop the reaction. The tubes were inserted to 10,000 events 
cytometer to get the final result sheet, that recorded one negative example 
and another positive example of the samples required. This was expressed by 
a dot plot. 
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Results 
Patients' characteristics 
A)   Leishman's staining 
In normal healthy controls, the basic blood cells are found clearly; In 
the CT group all blood cells were almost severely damaged. WBCs are burst 
and RBCs are overlapping at 1st cycle, 2nd cycle, and 3rd cycle of treatment. 
As for the MF group notable improvements were seen in which the 
neutrophils were retained with MF treatment and the biconcave shape of 
RBCs was greatly maintained gradually at 1st cycle 2nd cycle and 3rd cycle. 
 B)   Flow cytometric analysis of BCRP and MicroRNA 
 The current study clarified that the values of BCRP at the third dose of 
(CT + MF) group was still higher than normal group but these values were 
less than that of (CT) group. This revealed the basic role of BCRP as multi-
drug resistant although MF succeeded, to some extent in reducing these 
values (Table 1).  
Table 2 displayed that MF at the third dose of treatment regained the 
normal value for miRNA (mean ± SD: 49.92 and median: 49.47), A 
statistical significant conclusion was recorded for the third group (CT + MF) 
exhibiting that MF had its role in reducing miRNA. This decrease in miRNA 
in turn represented the refinements in this group as a result of MF targeting 
miRNA.  
Statistically in table 3, it had been shown that correlations existed 
between BCRP and MiRNA expressions and patients' outcome especially 
after MF medication.  
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Table 1. Comparison between the studied groups according to BCRP 
 
Control 
group 
(n=5) 
CT group (doses) MF group (doses) 
F p 1st 
(n=25) 
2nd 
(n=25) 
3rd 
(n=25) 
1st 
(n=25) 
2nd 
(n=25) 
3rd 
(n=25) 
BCRP %          
Min. – Max. 1.05 – 50.34 66.22 – 98.13 
66.17 – 
98.12 
66.13 – 
98.04 
52.53 ± 
88.10 
44.98 – 
77.05 
44.15 – 
59.26 
71.327* <0.001* Mean ± SD. 26.29 ± 2.55 83.59 ± 9.74 83.46 ± 9.68 83.03 ± 9.68 63.54 ± 6.93 60.59 ± 8.35 51.87 ± 3.24 
Median 27.18 85.65 85.60 85.59 66.13 60.86 51.16 
p1  <0.001* <0.001* <0.001* <0.001* <0.001* <0.001*   
p2     <0.001* 0.866 <0.001*   
F: F test (ANOVA) 
p1: p value for Post Hoc test (LSD) for comparing between control and each other group 
p2: p value for Post Hoc test (LSD) for comparing between CT group 1st with MF group 1st, CT group 2nd with MF group 2nd and CT group  3rd 
with MF group 3rd 
*: Statistically significant at p ≤ 0.05 
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Table 2. Comparison between the studied groups according to MiRNA 
 
Control 
group 
(n=5) 
CT group (doses) MF group (doses) 
F p 1st 
(n=25) 
2nd 
(n=25) 
3rd 
(n=25) 
1st 
(n=25) 
2nd 
(n=25) 
3rd 
(n=25) 
MiRNA %          
Min. – Max. 43.56 – 55.96 
59.27 – 
93.42 
59.20 – 
93.40 
59.0 -
93.14 
40.22 – 
64.76 
40.90 – 
62.17 
43.16 – 
59.72 51.0
65* <0.001
* Mean ± SD. 49.36 ± 5.59 
76.69 ± 
10.13 
76.58 ± 
10.12 
76.21 ± 
10.21 
55.37 ± 
7.99 
54.05 ± 
6.66 
49.92 ± 
4.62 
Median 49.0 77.09 76.92 76.61 59.24 55.43 49.47 
p1  <0.001* <0.001* <0.001* 0.150 0.261 0.893   
p2     <0.001* <0.001* <0.001*   
F: F test (ANOVA) 
p1 : p value for Post Hoc test (LSD) for comparing between control and each other group 
p2 : p value for Post Hoc test (LSD) for comparing between CT group II 1st with MF group III 1st , CT group II 2nd with MF group III 2nd and CT 
group II 3rd with MF group III 3rd 
*: Statistically significant at p ≤ 0.05 
 
Table 3. Correlation between BCRP with MiRNA in each studied group 
BCRP 
MiRNA 
r p 
Control 0.128 0.838 
Group II 1st dose CT 0.508* 0.010 
Group II 2nd dose CT 0.514* 0.009 
Group II 3rd dose CT 0.517* 0.008 
Group III 1st dose CT + MF 0.644* 0.001 
Group III 2nd dose CT + MF 0.328 0.109 
Group III 3rd dose CT + MF 0.249 0.231 
r: Pearson coefficient 
*: Statistically significant at p ≤ 0.05 
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C) Flow cytometric analysis of results by dot plot 
1. Flow cytometric results of BCRP 
i) The control group (n=5) 
  
ii) The CT group (n=25)  
a) At the first cycle of treatment 
  
b) At the second cycle of treatment 
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c) At the third cycle of treatment 
  
iii) The CT plus MF group (n=25) 
a) At the first cycle of treatment 
  
b) At the second cycle of treatment 
  
c) At the third cycle of treatment 
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2. Flow cytometric results of miRNA 
i) The control group (n=5)  
  
ii) The CT group (n=25)  
a) At the first cycle of treatment 
  
b) At the second cycle of treatment 
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c) At the third cycle of treatment 
  
iii) The CT plus MF group (n=25) 
a) At the first cycle of treatment 
  
b) At the second cycle of treatment 
European Scientific Journal October 2016 edition vol.12, No.30  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
388 
  
c) At the third cycle of treatment 
  
 
Discussion 
BC is a major health problem that will affect approximately 1.3 million 
women worldwide. In 2013 the American cancer society, estimated that 
more than 296,000 women and 2,240 men were diagnosed with BC, 
Recently, researchers at the NCI projected that the overall BC incidence rate 
will stay the same through 2016. CT plays a key role in the treatment of BC; 
however, the widespread resistance to CT often results in the treatment 
failure. Drug resistance to chemotherapeutic agents accounted for treatment 
failure in more than 90% of patients with metastatic cancer. 
Previous studies indicated that BCRP conferred an atypical MDR 
phenotype. A transfectant BCRP expression cell model was established and 
utilized to screen clinical anticancer drugs in vitro. In addition, BCRP 
expression was reported in 20–30% of clinical BC tissue specimens. A recent 
result suggested that BCRP expression may contribute to the failure of BC 
CT to a certain extent. 
The present results showed that the control group had the lowest values 
for BCRP (mean: 26.29). The (CT) group had the highest values (mean: 
83.03) after the third cycle and near this value post first and second doses. 
The MF group situated between the lowest and highest values (mean 51.87) 
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after third cycle. These values indicated the basic role of BCRP as MDR and 
reflected, in addition the success of MF in amelioration of elevated values of 
BCRP in the third group (CT + MF). 
Present results were coincided with many literatures that revealed 
increased values for BCRP either in BC or in other types of cancers. Current 
results were coincided with this consideration stating that the occurrence of 
BCRP is higher in BC patients group (CT) than control group. But after the 
MF treatment this group demonstrated lower expression due to MF's indirect 
effect on the role of BCRP as a drug resistant. 
With respect to miRNAs, these compounds are evolutionarily 
conserved, endogenous, single-stranded, noncoding RNA molecules that are 
reported to be involved in many biological processes, including cell 
proliferation, apoptosis, and tumorigenesis, through their regulation of gene 
expression. Most miRNAs bind to target sequences located within the 3'UTR 
of mRNAs by base pairing, resulting in the cleavage of target mRNAs or 
repression of their translation. 
Regarding present results, the same values of miRNA were more or 
less observed in both normal and (CT + MF) groups (mean: 49.36 and 49.92 
and the median: 49.0 and 49.47 respectively). The elevated miRNA values 
were recorded in second group (CT) at all cycles. These values indicated that 
the MF revealed its role in reducing miRNA, which in turn represented the 
improvements in this group (CT + MF) and this amelioration was dose-
dependent. These results were coincided with previous reports elucidated.  
Eventually miRNAs which are found intracellularly and extracellularly 
are functioning in mainly the regulation of gene expression, apoptosis and 
tumorigenesis. Moreover, the recent role of miRNAs in BC is diagnosis and 
treatment. 
Since miRNAs were dysregulated in both normal and malignant tissues 
of the breast and other body fluids. Therefore their expression was varying in 
the same tissue with levels up and down and sometimes vice versa with 
respect to previous studies. So the amount of miRNA in control group was 
lower than that of the patients groups (group CT & MF). In addition 
miRNAs act as oncogenes and tumor suppressor genes and vice versa inside 
the cell under certain circumstances. In current results, this dysregulation of 
miRNA was clearly noted. Before the treatment with MF in the (CT) group 
miRNAs expression was found in a higher level that could be due to miRNA 
biogenesis pathways, in which the Cis regulation targeting of mRNA is done 
so in this situation the occurrence of miRNAs was highly found in the results 
as they may be oncogenes.  
On the other hand after the addition of MF medication, MF could acts 
as a miRNA inhibitor. In this situation the occurrence of miRNAs was found 
in (CT + MF) group to be lower than the (CT) group only. This reduction in 
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miRNA may reflect its role as tumor suppressor gene instead of oncogene. 
This in turn highlighted the role of MF in targeting miRNA.  
Finally the role of MF was well illustrated in targeting of miRNA to 
reinforce BC medication. In conclusion we can advise oncologists to use MF 
equivalent to CT in the recommended doses. MF led to a significant 
reduction in untoward effect of CT and cancer and improved the patients' 
outcome which may be due to its role as selectively killer for the cells that 
were chemoresistant.  
 
Fig. 1: Leishman's staining of control 
groupX1000(e:eosinophil,b:basophil,m:monocyte,l:lymphocyte,n:neutrophil,
p:platelets). 
 
 
Fig. 2: Leishman's staining of CT group 
X1000(e:eosinophil,b:basophil,m:monocyte,l:lymphocyte,n:neutrophil,p:plat
elets,r:rbcs). 
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Fig. 3: Leishman's staining of MF group 
X1000(e:eosinophil,b:basophil,m:monocyte,l:lymphocyte,n:neutrophil,p:plat
elets,r:rbcs). 
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